Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Bioregenx (BRGX) Revenue (2022 - 2025)

Bioregenx has reported Revenue over the past 4 years, most recently at $385641.0 for Q4 2025.

  • For Q4 2025, Revenue fell 16.25% year-over-year to $385641.0; the TTM value through Dec 2025 reached $1.9 million, down 20.75%, while the annual FY2025 figure was $1.9 million, 20.75% down from the prior year.
  • Revenue for Q4 2025 was $385641.0 at Bioregenx, down from $507755.0 in the prior quarter.
  • Over five years, Revenue peaked at $1.1 million in Q1 2023 and troughed at $7704.0 in Q1 2022.
  • A 4-year average of $479231.4 and a median of $511451.0 in 2025 define the central range for Revenue.
  • Biggest five-year swings in Revenue: skyrocketed 13861.38% in 2023 and later plummeted 48.91% in 2024.
  • Year by year, Revenue stood at $8914.0 in 2022, then surged by 7506.1% to $678008.0 in 2023, then tumbled by 32.08% to $460489.0 in 2024, then decreased by 16.25% to $385641.0 in 2025.
  • Business Quant data shows Revenue for BRGX at $385641.0 in Q4 2025, $507755.0 in Q3 2025, and $445970.0 in Q2 2025.